Literature DB >> 3390030

Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis.

M P Amato1, L Fratiglioni, C Groppi, G Siracusa, L Amaducci.   

Abstract

Interexaminer agreement in the use of quantitative scales for the evaluation of neurological deficits is essential to the reliability of clinical data from cooperative studies on multiple sclerosis. In this study, four neurologists, arranged into six pairs, examined 24 patients with definite multiple sclerosis and assessed each functional system and disability on the Kurtzke scale. As expressed by the kappa index, interobserver agreement was rather low, ranging from 30% to 50%. Sensory and mental functions turned out to be the most variable. The kappa indexes reached values above 85%, when raters who differed by no more than one point were considered as agreeing. A point difference on the scale of, at most, two units seemed to be a reliable index of clinical change. Moreover, these results pointed to the necessity for a specific training program for raters and for periodic control of interobserver variability in multicenter surveys.

Entities:  

Mesh:

Year:  1988        PMID: 3390030     DOI: 10.1001/archneur.1988.00520310052017

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  23 in total

1.  Use of different outcome measures in randomised studies of malignant glioma can significantly alter the interpretation of time to progression: reanalysis of the MRC BR2 study.

Authors:  J Chataway; S Stenning; N Bleehen; R Grant
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

2.  Walking function in clinical monitoring of multiple sclerosis by telemedicine.

Authors:  Núria Sola-Valls; Yolanda Blanco; Maria Sepúlveda; Sara Llufriu; Elena H Martínez-Lapiscina; Delon La Puma; Francesc Graus; Pablo Villoslada; Albert Saiz
Journal:  J Neurol       Date:  2015-05-10       Impact factor: 4.849

3.  European validation of a standardized clinical description of multiple sclerosis.

Authors:  Maria Pia Amato; Jerome Grimaud; Iuliana Achiti; Maria Letizia Bartolozzi; Patrice Adeleine; Hans-Peter Hartung; Ludwig Kappos; Alan Thompson; Maria Trojano; Sandra Vukusic; Christian Confavreux
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

4.  Telemedicine for Monitoring MS Activity and Progression.

Authors:  Nuria Sola-Valls; Yolanda Blanco; Maria Sepúlveda; Eugenia Martinez-Hernandez; Albert Saiz
Journal:  Curr Treat Options Neurol       Date:  2015-11       Impact factor: 3.598

Review 5.  What We Learned from The History of Multiple Sclerosis Measurement: Expanded Disability Status Scale.

Authors:  Bilge Piri Çinar; Yüksel Güven Yorgun
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

6.  Multiple Sclerosis: What can family physicians do?

Authors:  S A Hashimoto; T I Jiwa
Journal:  Can Fam Physician       Date:  1991-10       Impact factor: 3.275

7.  Treatment of walking impairment in multiple sclerosis with dalfampridine.

Authors:  Andrew R Blight
Journal:  Ther Adv Neurol Disord       Date:  2011-03       Impact factor: 6.570

8.  Contribution of relapses to disability in multiple sclerosis.

Authors:  Claire Hirst; Gillian Ingram; Owen Pearson; Trevor Pickersgill; Neil Scolding; Neil Robertson
Journal:  J Neurol       Date:  2008-01-23       Impact factor: 4.849

Review 9.  Treatment trials in progressive MS--current challenges and future directions.

Authors:  Marcus W Koch; Gary Cutter; Peter K Stys; V Wee Yong; Luanne M Metz
Journal:  Nat Rev Neurol       Date:  2013-07-30       Impact factor: 42.937

10.  Recording neurological impairment in clinical trials of glioma.

Authors:  R Grant; J Slattery; A Gregor; I R Whittle
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.